Main Article Content
Objective: The pandemic caused by Sars‑CoV‑2 (COVID‑19) has changed dramatically individuals’ life worldwide. The implication of measures of public health protection, the social distance and isolation, the lockdown and the decrease of social life activities caused escalated anxiety, depression, physical inactivity on the one hand and widespread unemployment and financial crisis on the other hand. Preliminary studies during COVID‑19 pandemic reported an increase in the use of psychoactive substances, including alcohol and cannabis (CB). The latter has been linked with harmful cardiovascular and respiratory effects (eg. lung cancer, bronchitis and pulmonary emphysema). Especially people with substance use disorders were further stressed by the current circumstances and were found to intensify consumption of cannabinoids (1-4). This short review focuses on the possible cardiovascular impact of CB abuse in the era of Covid-19 pandemic. It aims to stress the worldwide clinical attention and the clinicians’ awareness on the development of specific prevention and intervention strategies against CB addiction during pandemics.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
2. Satre DD, Iturralde E, Ghadiali M, Young‑Wolff KC, Campbell CI, Leibowitz AS, et al. Treatment for anxiety and substance use disorders during the COVID‑19 pandemic: challenges and strategies. J Addict Med. 2020;14(6):e293–6. https ://doi.org/10.1097/ADM.00000 00000 00075 5.
3. Dumas TM, Ellis W, Litt DM. What does adolescent substance use look like during the COVID‑19 pandemic? Examining changes in frequency, social contexts, and pandemic‑related predictors. J Adolesc Heal. 2020;67(3):354–61.
4. Avena NM, Simkus J, Lewandowski A, Gold MS, Marc N. Potenza. Substance Use Disorders and Behavioral Addictions During the COVID-19 Pandemic and COVID-19-related Restrictions. Front. Psychiatry | doi: 10.3389/fpsyt.2021.653674
5. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2018 National Survey on Drug Use and Health: Detailed Tables. Available online: https://www.samhsa.gov/data/report/201 8-nsduh-detailed-tables (accessed on 14 December 2019).
6. Azofeifa A, Mattson M.E, Schauer G, McAfee T, Grant A, Lyerla, R. National estimates of MJ use and related indicators—National Survey on Drug Use and Health, United States, 2002–2014. MMWR Surveill. Summ. 2016, 65, 1–25.
7. Subramaniam VN, Menezes AR, DeSchutter A, Lavie CJ. The Cardiovascular Effects of MJ: Are the Potential Adverse Effects Worth the High? Missouri Medicine 2019;(March/April) 116:2
8. Terry-McElrath YM, O’Malley PM, Johnston LD. Alcohol and MJ use patterns associated with unsafe driving among U.S. high school seniors: high use frequency, concurrent use, and simultaneous use. Journal of studies on alcohol and drugs. 2014;75:378-389.
9. Hodcroft CJ, Rossiter MC, Buch AN. CB-associated myocardial infarction in a young man with normal coronary arteries. J Emerg Med. 2014;47:277-281.
10. Dahdouh Z, Roule V, Lognone T, Sabatier R, Grollier G. CB and coronary thrombosis: What is the role of platelets? Platelets. 2012;23:243-245.
11. Jouanjus E, Pharm D, Lapeyre-Mestre M, Micallef J. CB Use: Signal of Increasing Risk of Serious Cardiovascular Disorders. The French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on CB Complications*. J Am Heart Assoc. 2014 ;3:e000638 doi: 10.1161/JAHA.113.000638
12. Singh A, Saluja S, Kumar A, Agrawal S, Thind M, Nanda S, Shirani J. Cardiovascular Complications of MJ and Related Substances: A Review. Cardiol Ther (2018) 7:45–59 https://doi.org/10.1007/s40119-017-0102-x
13. Williams JC, Klein TW, Goldberger BA, Sleasman JW, Mackman N, Goodenow MM. D(9)-Tetrahydrocannabinol (THC) enhances lipopolysaccharide stimulated tissue factor in human monocytes and monocyte-derived microvesicles. J Inﬂamm (Lond). 2015;12:39.
14. Dahdouh Z, Roule V, Lognone ´ T, Sabatier R, Grollier G. CB and coronary thrombosis: what is the role of platelets? Platelets. 2012;23:243–5.
15. Hodcroft CJ, Rossiter MC, Buch AN. CB-associated myocardial infarction in a young man with normal coronary arteries. J Emerg Med. 2014;47:277–81.
16. VelibeyY, SahinS, TanıkO, KeskinM, BolcaO, ErenM. Acute myocardial infarction due to MJ smoking in a young man: guilty should not be underestimated. Am J Emerg Med. 2015;33:1114.e1–3.
17. Artiles, A.; Awan, A.; Karl, M.; Santini, A. Cardiovascular eﬀects of CB (MJ): A timely update. Wiley 2019. 33;1592–1594.
18. Karschner EL, Darwin WD, McMahon RP, Liu F, Wright S, Goodwin RS, et al. Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther. 2011;89:400–7.
19. Jicha CJ, Lofwall MR, Nuzzo PA, Babalonis S, Elayi SC, Walsh SL. Safety of oral dronabinol during opioid withdrawal in humans. Drug Alcohol Depend. 2015;157:179–83.
20. Desai, R.; Fong, H.K.; Shah, K.; Kaur, V.P.; Savani, S. Rising trends in hospitalizations for cardiovascular events among young CB users (18–39 years) without other substance abuse. Medicina (B. Aires). 2019;55: 1–6.
21. Jouanjus E, Raymond V, Lapeyre-Mestre M, Wolff V. What is the current knowledge about the cardiovascular risk for users of CB-based products? A systematic review. Curr Atheroscler Rep. 2017;19:26.
22. Sandeep Singla, Rajesh Sachdeva, JawaharL. Mehta. Cannabinoids and Atherosclerotic Coronary Heart Disease. Clin.Cardiol. 2012;35 (6):329–335(). DOI:10.1002/clc.21962
23. Hartung, B.; Kauferstein, S.; Ritz-Timme, S.; Daldrup, T. Sudden unexpected death under acute inﬂuence of CB. Forensic Sci. Int. 2014, 237, 11–14.
24. Gunawardena MD, Rajapakse S, Herath J, Amarasena N. Myocardial infarction following CB induced coronary vasospasm. BMJ Case Rep. 2014;2014.
25. Casier I, Vanduynhoven P, Haine S, Vrints C, Jorens PG. Is recent CB use associated with acute coronary syndromes? An illustrative case series. Acta cardiologica. 2014;69:131-136.
26. I. Kotsalou, P. Georgoulias, I. Karydas, S. Fourlis, Ch. Sioka, A. Zoumboulidis, N. Demakopoulos. Α rare case of myocardial infarction and ischemia in a CB-addicted patient. Clin Nucl Med. 2007 Feb; 32(2): 130-1
27. Gunawardena MDVM, Rajapakse S, Herath J, Amarasena N. Myocardial infarction following CB induced coronary vasospasm. BMJ Case Rep. 2014;2014. https://doi.org/10.1136/bcr-2014207020.
28. Stanley, C.; O’Sullivan, S.E. Vascular targets for cannabinoids: Animal and human studies. Br. J. Pharmacol. 2014, 171, 1361–1378.
29. Richards, J.R.; Bing, M.L.; Moulin, A.K.; Elder, J.W.; Robert, T.; Summers, P.J.; Laurin, E.G.; Richards, J.R.; Bing,M.L.; Moulin ,A.K.; etal. CB use and acute coronary syndrome. Clin. Toxicol. 2019;3650:831–841.
30. Draz, E.I.; Oreby, M.M.; Elsheikh, E.A.; Khedr, L.A.; Atlam, S.A. MJ use in acute coronary syndromes. Am. J. Drug Alcohol Abuse. 2017; 43: 576–582.
31. OrsiniJ, BlaakC, RajayerS, GurungV, TamE, Morante J, Shamian B, Malik R. Prolonged cardiac arrest complicating a massive ST-segment elevation myocardial infarction associated with MJ consumption. J Community Hosp Intern Med Perspect. 2016;. https://doi.org/10.3402/jchimp.v6.31695.
32. Ghannem M, Belhadj I, Tritar A, et al. (CB and acute coronary syndrome with ST segment elevation). Ann Cardiol Angeiol (Paris). 2013;62:424-428.
33. Bailly C, Merceron O, Hammoudi N, Dorent R, Michel PL. CB induced acute coronary syndrome in a young female. International journal of cardiology. 2010;143:e4-6.
34. Lee JD, Schatz D, Hochman J. CB and Heart Disease. Journal of the American College of Cardiology. 2018;71:2552.
35. Reis, J.P.; Auer, R.; Bancks, M.P.; Goﬀ, D.C., Jr.; Lewis, C.E.; Pletcher, M.J.; Rana, J.S.; Shikany, J.M.; Sidney, S. Cumulative lifetime MJ use and incident cardiovascular disease in MiddleAge: The Coronary Artery Risk Development in Young Adults (CARDIA) study. AJPH Res. 2017; 107: 601–606.
36. Latif Z, Garg N. The impact of marijuana on the cardiovascular system: a review of the most common cardiovascular events associated with marijuana use. Journal of clinical medicine. 2020 Jun;9(6):1925.
37. Kariyanna, P.T, Wengrofsky P, Jayarangaiah A, Haseeb, S. MJ and cardiac arrhythmias: A scoping study. Int. J. Clin. Res. Trials. 2019;4:1–11.
38. Singh,A, Saluja,S, Kumar,A, Agrawal S. Cardiovascular complications of MJ and related substances: A review. Cardiol. Ther. 2018;7:45–59.
39. Frost L, Mostofsky E, Rosenbloom J.I. MJ use and long term mortality among survivors of acute myocardial infarction. Am. Heart J. 2013;165:170–175.